This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 Dec;1(9):1217-8.

doi: 10.1001/jamaoncol.2015.2340.

Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making

Elisa F Long¹, Patricia A Ganz²

Affiliations

Affiliations

¹ Anderson School of Management, University of California, Los Angeles.
² Division of Cancer Prevention and Control Research and Jonsson Comprehensive Cancer Center, University of California, Los Angeles3Fielding School of Public Health, University of California, Los Angeles.

PMID: 26335890
DOI: 10.1001/jamaoncol.2015.2340

Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making

Elisa F Long et al. JAMA Oncol. 2015 Dec.

. 2015 Dec;1(9):1217-8.

doi: 10.1001/jamaoncol.2015.2340.

Authors

Elisa F Long¹, Patricia A Ganz²

Affiliations

¹ Anderson School of Management, University of California, Los Angeles.
² Division of Cancer Prevention and Control Research and Jonsson Comprehensive Cancer Center, University of California, Los Angeles3Fielding School of Public Health, University of California, Los Angeles.

PMID: 26335890
DOI: 10.1001/jamaoncol.2015.2340

No abstract available

PubMed Disclaimer

Similar articles

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S. Pataky R, et al. BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339. BMC Cancer. 2013. PMID: 23837641 Free PMC article.
Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
de Bock GH, Vermeulen KM, Jansen L, Oosterwijk JC, Siesling S, Dorrius MD, Feenstra T, Houssami N, Greuter MJ. de Bock GH, et al. Br J Cancer. 2013 Apr 30;108(8):1579-86. doi: 10.1038/bjc.2013.149. Epub 2013 Apr 11. Br J Cancer. 2013. PMID: 23579217 Free PMC article.
Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA, Greuter MJW, Obdeijn IM, Oosterwijk JC, Feenstra TL, Houssami N, de Bock GH. Phi XA, et al. Breast. 2019 Jun;45:82-88. doi: 10.1016/j.breast.2019.03.004. Epub 2019 Mar 12. Breast. 2019. PMID: 30904701
Cost-effectiveness of mammography, MRI, and ultrasonography for breast cancer screening.
Feig S. Feig S. Radiol Clin North Am. 2010 Sep;48(5):879-91. doi: 10.1016/j.rcl.2010.06.002. Radiol Clin North Am. 2010. PMID: 20868891 Review.
Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
Calderon-Margalit R, Paltiel O. Calderon-Margalit R, et al. Int J Cancer. 2004 Nov 10;112(3):357-64. doi: 10.1002/ijc.20429. Int J Cancer. 2004. PMID: 15382059 Review.

See all similar articles

Cited by

Evaluation of disparities in perceived healthcare discrimination among BRCA1/2-positive women from medically underserved populations.
Dibble KE, Connor AE. Dibble KE, et al. Women Health. 2023 Aug 9;63(7):539-550. doi: 10.1080/03630242.2023.2237610. Epub 2023 Jul 18. Women Health. 2023. PMID: 37461380
Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles.
Elias K, Smyczynska U, Stawiski K, Nowicka Z, Webber J, Kaplan J, Landen C, Lubinski J, Mukhopadhyay A, Chakraborty D, Connolly DC, Symecko H, Domchek SM, Garber JE, Konstantinopoulos P, Fendler W, Chowdhury D. Elias K, et al. Nat Commun. 2023 Jun 8;14(1):3350. doi: 10.1038/s41467-023-38925-4. Nat Commun. 2023. PMID: 37291133 Free PMC article.
Attitudes and beliefs regarding race-targeted genetic testing of Black people: A systematic review.
Iltis AS, Rolf L, Yaeger L, Goodman MS, DuBois JM. Iltis AS, et al. J Genet Couns. 2023 Apr;32(2):435-461. doi: 10.1002/jgc4.1653. Epub 2023 Jan 16. J Genet Couns. 2023. PMID: 36644818 Free PMC article.
A simple framework to identify optimal cost-effective risk thresholds for a single screen: Comparison to Decision Curve Analysis.
Katki HA, Bebu I. Katki HA, et al. J R Stat Soc Ser A Stat Soc. 2021 Jul;184(3):887-903. doi: 10.1111/rssa.12680. Epub 2021 Mar 23. J R Stat Soc Ser A Stat Soc. 2021. PMID: 35702631 Free PMC article.
BRCA testing and testing results among women 18-65 years old.
Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF. Guo F, et al. Prev Med Rep. 2022 Feb 19;26:101738. doi: 10.1016/j.pmedr.2022.101738. eCollection 2022 Apr. Prev Med Rep. 2022. PMID: 35242503 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal